Form D · Other
MET Biotechnology Inc.
Culver City, CA · CIK 0002011292
Offering snapshot reported Feb 9, 2024 · SEC filing
- Reported sold
- $2M Offering amount: $2M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 25, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 9, 2024 | Initial | $2,000,000 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-504896
Series Seed-1 and Series Seed-2 Preferred Stock, and the Common Stock issuable upon conversion thereof.
Source: Form D, filed Feb 9, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Pei Yu Chiou | Director |
| Michael A. Teitell | Director |
| Ting Hsiang Wu | Director, Executive |
| Tung Yu Wu | Director |
Issuer details
Industry: Other (See others in industry)
Address:
10827 Whitburn Street
Culver City, CA, 90230
Culver City, CA, 90230